GlobeNewswire Inc | Dec 13, 2021 04:01PM EST

December 13, 2021

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced it was added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to market open on Monday, December 20, 2021.

The NBI was launched in 1993 and includes securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceutical companies. Companies in the NBI must meet eligibility requirements, including average daily trading volume, minimum market capitalization, and other criteria. The index is evaluated annually in December and serves as the basis for the iShares NASDAQ Biotechnology Index Fund.

For more information about the NASDAQ Biotechnology Index, please visit nasdaqomx.com.

About Sensei BiotherapeuticsSensei Biotherapeutics is a biopharmaceutical company engaged in discovery, development, and delivery of next generation immunotherapies with an initial focus on treatments for cancer. Sensei has developed two unique approaches its TMAb (Tumor Microenvironment Activated biologics) platform, comprising unique human monoclonal antibodies and alpaca derived nanobodies that are selectively active in the tumor microenvironment, and its ImmunoPhage platform that leverages bacteriophage to fully engage the immune system. Using its TMAb platform, the company has developed SNS-101, an antibody-based therapeutic in lead generation targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). Using the ImmunoPhage platform, Sensei is developing a library of ImmunoPhage, called Phortress, with multiple tumor-associated antigens to create a personalized, yet off-the-shelf cocktail approach for treating cancer patients. The platform is designed to enable efficient, scalable and cost-effective manufacturing to support all of Senseis clinical programs. SNS-401-NG is an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma. For more information, please visitwww.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Cautionary Note Regarding Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and are based on Senseis current beliefs and expectations. These forward-looking statements include expectations regarding the development of Senseis product candidates and platforms. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as preclinical discovery and development, conduct of clinical trials and related regulatory requirements, Senseis reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in Senseis Annual Report on Form10-Kfiled with the U.S. Securities and Exchange Commission (SEC) on March30, 2021 and Senseis other Periodic Reports filed with the SEC.Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:Erin ColganSVP, Finance and Administration Sensei Biotherapeuticsecolgan@senseibio.com